The Modified Mucosal Inflammation Noninvasive Index and Endoscopic Remission in Adults with Crohn's Disease

Dotan Yogev, Bram Verstockt, Axel Dignass, Gili Focht, Ohad Atia, Iris Dotan, Severine Vermeire, Dan Turner*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The Mucosal Inflammation Noninvasive Index is a validated noninvasive tool to assess endoscopic remission in pediatric Crohn s disease. In this study, we evaluated a modified version of the Mucosal Inflammation Noninvasive Index on adult cohorts to explore its validly in adult Crohn s disease.

Original languageAmerican English
Pages (from-to)1170-1174
Number of pages5
JournalInflammatory Bowel Diseases
Volume29
Issue number7
DOIs
StatePublished - 1 Jul 2023

Bibliographical note

Funding Information:
D.T. has received in the last 3 years consultation fees, research grants, royalties, or honoraria from Janssen, Pfizer, the Hospital for Sick Children, Ferring, AbbVie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, Thermo Fisher, BMS, and Sorriso Pharma. G.F. has received in the last 3 years consultation fees from AbbVie and Lilly. S.V. has received research support from AbbVie, J&J, Pfizer, Galapagos, and Takeda; consulting and/or speaking fees from AbbVie, Abivax, Agomab, Arena Pharmaceuticals, Avaxia, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Janssen, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, and Tillotts Pharma AG. B.V. has received research support from Pfizer; speaker fees from AbbVie, Biogen, Bristol-Myers Squibb, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion, and Viatris; and consultancy fees from AbbVie, Alimentiv, Applied Strategic, Atheneum, Bristol-Myers Squibb, Galapagos, Guidepoint, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillotts Pharma, and Viatris. I.D. has received in the last 3 years consultation fees, research grants, or honoraria from Janssen, Pfizer, AbbVie, Takeda, Genentech/Roche, Neopharm, Ferring, Rafa Laboratories, Falk Pharma, Nestlé, Gilead, Galapagos, Celgene/BMS, Arena, Sublimity, Celltrion, Wilbio, Cambridge Healthcare, Abbott, Food Industries Organisation, Altman, Sangamo, Athos, Integra Holdings, Medscape, Mediahuset, and Iterative scopes. A.D. has received fees for participation in clinical trials and review activities (ie, data monitoring boards, statistical analysis, and endpoint committees) from AbbVie, Celgene/Bristol-Myers Squibb, Falk Foundation, Gilead, Janssen, and Pfizer; consultancy fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celgene/Bristol-Myers Squibb, Eli Lilly, Falk, Ferring, Fresenius Kabi, Galapagos, Gilead, Janssen, MSD, Pfizer, Pharmacosmos, Roche/Genentech, Sandoz/Hexal, Takeda, Tillotts, and Vifor; payment for lectures, including service on the Speakers Bureau, from AbbVie, Eli Lilly, Falk Foundation, Ferring, Gilead/Galapagos, Janssen, MSD, Pfizer, Takeda, Tillotts, and Vifor; and payment for development of educational presentations from Ferring and Tillotts.

Funding Information:
BV is supported by the Clinical Research Fund (KOOR) of the University Hospitals Leuven and the Research Council of KU Leuven.

Publisher Copyright:
© 2023 Oxford University Press. All rights reserved.

Fingerprint

Dive into the research topics of 'The Modified Mucosal Inflammation Noninvasive Index and Endoscopic Remission in Adults with Crohn's Disease'. Together they form a unique fingerprint.

Cite this